Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Electrochemotherapy for Breast Cancer-Results From the INSPECT Database

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hereditary breast cancer: clinical, pathological and molecular characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies

    Research output: Contribution to journalJournal articleResearch

  2. Calcium electroporation for recurrent head and neck cancer: A clinical phase I study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases

    Research output: Contribution to journalReviewResearchpeer-review

  • Louise Wichmann Matthiessen
  • Mohammed Keshtgar
  • Pietro Curatolo
  • Christian Kunte
  • Eva-Maria Grischke
  • Joy Odili
  • Tobian Muir
  • David Mowatt
  • James P Clover
  • Se Hwang Liew
  • Karin Dahlstroem
  • Jackie Newby
  • Valerie Letulé
  • Eva Stauss
  • Alison Humphreys
  • Shramana Banerjee
  • Annette Klein
  • Roberta Rotunno
  • Francesca de Terlizzi
  • Julie Gehl
View graph of relations

BACKGROUND: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer.

PATIENTS AND METHODS: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m2) of bleomycin.

RESULTS: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed.

CONCLUSION: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

Original languageEnglish
JournalBreast Cancer: Basic and Clinical Research
Issue number5
Pages (from-to)e909-e917
Publication statusPublished - Oct 2018

ID: 56562857